Drospirenone--a new 17 alpha-spironolactone derivate is a progestin with aldosterone receptor antagonism activity (PARA) thanks to which it decreases sodium and fluid retention.
The aim: The aim of our study was to estimate the electrolytes level and renal function parameters in blood during the therapy of low dose oral contraceptive containing drospirenone.
Material and methods: The group consisted of 22 young women in mean age 25,9 +/- 4,3 years, without contraindications to hormonal contraception used specimen containing 20 microg ethinyloestradiol and 3.0 mg drospirenone during 12 cycles. Blood levels of electrolytes (sodium, potassium, calcium, phosphorus and chloride) and renal function parameters (creatinine, urea and uric acid) were evaluated before and after 3, 6 and 12 cycles of the treatment
Results: There were no statistically significant differences observed in serum concentration of electrolytes and renal function parameters.
Conclusion: The therapy of a low dose oral contraceptive containing 20 microg ethinyloestradiol and 3.0 mg drospirenone does not influence the electrolyte equilibrium and renal function.